First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results
medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…
AI Summary: A Phase I study reports that adding stem‑cell therapy to standard fetal surgery for spina bifida is safe and may reverse fetal brain damage. Early clinical results published in a leading journal show feasibility and encouraging biological effects, setting the stage for larger trials and cautious optimism among researchers and clinicians.
Boehringer wins accelerated approval for first-line use of lung cancer drug
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.
Novartis to build $23B radioligand therapy site
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.
Patient dies in MacroGenics' cancer study, FDA puts trial on hold
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.
More Research, Less Cancer: £250m raised to transform the future of cancer research
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
AI Summary: The More Research Less Cancer campaign has reached a £250 million fundraising milestone to accelerate cancer research, support translational projects, and expand patient-focused initiatives. Donor momentum will underwrite discovery science and clinical translation, giving researchers more runway to turn promising lab findings into treatments patients might actually see.
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.
Gilead to acquire cell therapy manufacturer for $7.8B
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin
esmo - Findings from the KEYNOTE-905/EV-303 study
AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.
A novel C. diff vaccine shows promise
Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…
AI Summary: Researchers at Vanderbilt have reported a novel experimental vaccine that prevents Clostridioides difficile infection and reduces recurrence in early studies, demonstrating strong protective immune responses. The work offers a much‑needed alternative to antibiotics and recurrent‑infection management, though larger clinical trials will be required to confirm safety, durability and real‑world impact.
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
AI Summary: Novartis has committed $100 million upfront to partner with Unnatural Products, acquiring access to a macrocyclic peptide platform designed to reach challenging protein targets. The deal accelerates Novartis’ efforts to expand into next‑generation peptide therapeutics and bolsters its early R&D pipeline with technology aimed at previously “undruggable” targets.
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice
livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.
AI Summary: Scientists reported a nasal-spray vaccine that protected mice against a range of respiratory viruses, bacteria and even a common allergen, a tantalizing step toward a universal respiratory vaccine. The animal data look promising, but human trials are essential before anyone ditches annual shots for a single spritz and a prayer.
Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment
discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.
AI Summary: A comparative genomics study finds the household cat shares key cancer mutations with humans across several tumor types, offering a practical animal model for understanding tumor biology and testing therapies. Researchers suggest these feline-human parallels could accelerate translational oncology for both species, turning a once-dismissed pet anecdote into useful science.
Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV
medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…
AI Summary: Researchers mined the blood of pediatricians — occupationally exposed to many childhood viruses — to isolate highly potent antibodies, then combined them into a cocktail that neutralizes respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Preclinical results show strong neutralization and protection, offering a promising prophylactic or therapeutic option for infants and at-risk adults.
FDA formalizes one pivotal trial policy via NEJM perspective
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
AI Summary: The FDA has moved to make a single pivotal trial the new default for drug approvals, abandoning the long-standing two-study standard to speed access and ease OTC transitions. The policy, outlined by agency leaders and discussed in a NEJM perspective, raises questions about evidence thresholds and downstream safety monitoring. Welcome to faster approvals — now let's hope that lone study behaves.
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
AI Summary: After renewed discussions with the company, the FDA reversed its earlier stance and agreed to accept Moderna’s amended application for an mRNA seasonal influenza vaccine. Regulators will now evaluate the submitted safety and efficacy data to determine whether the shot meets approval standards — a regulatory about-face that will keep flu-watchers and investors awake.